A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Public ClinicalTrials.gov record NCT03720548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD. The study has two parts: * Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks; * Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.
Study identification
- NCT ID
- NCT03720548
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2018
- Primary completion
- May 13, 2019
- Completion
- May 13, 2019
- Last update posted
- Jun 4, 2019
2018 – 2019
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Collaborative Neuroscience Network - CNS | Long Beach | California | 90806 | — |
| Covance Clinical Research Inc | Daytona Beach | Florida | 32117 | — |
| Avail Clinical Research LLC | DeLand | Florida | 32720 | — |
| MD Clinical | Hallandale | Florida | 33009 | — |
| BioClinica Inc | Orlando | Florida | 32806 | — |
| IMIC, Inc. | Palmetto Bay | Florida | 33157 | — |
| Progressive Medical Research | Port Orange | Florida | 32127 | — |
| BioClinica Inc | The Villages | Florida | 32162 | — |
| Atlanta Center of Medical Research | Atlanta | Georgia | 30331 | — |
| Carolina Phase 1 Research (Wake M3) | Raleigh | North Carolina | 27612 | — |
| PRA Health Sciences | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03720548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2019 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03720548 live on ClinicalTrials.gov.